Examples of genetically informed therapies in PTCL. (A) Protocol for testing the JAK2 inhibitor ruxolitinib (Rux) in a T-PLL PDX with a BCR-JAK2 fusion. (B) Reduced spleen size and spleen disease burden, and increased apoptosis (Annexin V⁺) in residual T-PLL cells at day 8 of treatment. *P < .05 by 2-sided Student t test with Welch correction. (C) Pooled data showing consistent activity of the MDM2/MDMX inhibitor ALRN-6924 across 5 different p53–wild-type PTCL PDXs (5 mice per arm per PDX) after 8-day treatment. Each point indicates a mouse. Tumor was subcutaneous xenograft in 2 models or splenic in 3 disseminated, orthotopic models. Data reproduced from Ng et al with permission.³⁶